Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours
This article or press release has no online content. Please download the associated documents for more information.
You are now leaving the Ipsen Group section. If you would like to visit an affiliate section, please click Continue. The information provided on this section may not necessarily be applicable to the Ipsen Group.